Skip to main content
. 2018 Jun 25;57(10):1777–1788. doi: 10.1093/rheumatology/key161

Fig. 4.

Fig. 4

Work productivity and activity impairment-specific health problem

(A) absenteeism; (B) presenteeism; (C) work productivity; (D) activity impairment. The study was not designed to compare active treatment groups. *P ≤ 0.001 vs PBO; †P < 0.01; §P < 0.05. ADA: adalimumab; IXEQ4W/Q2W: ixekizumab every 4 or 2 weeks; N: number of patients in the analysis population; PBO: placebo; WPAI-SHP: work productivity and activity impairment-specific health problem.